Announced during the company's recent analyst day, the instrument could mark a major step in mass spectrometry's ongoing move into clinical applications.
After years of technical setbacks and challenges, mass spec-based clinical proteomics is "ready for prime time," a Thermo Fisher Scientific researcher told ProteoMonitor this week.
Thermo Fisher Scientific last week announced a collaboration with German diagnostics firm Immundiagnostik for development of mass spec-based assays for protein and peptide quantitation.
The findings suggest that guidelines for chronic kidney disease testing, which have come under increased scrutiny in recent years, could benefit from including albumin and cystatin C levels in definitions of the disease.
According to the patent, the company identified the proteins serum amyloid A and S-sulfonated transthyretin as biomarkers for myocardial infarction and developed a three-marker panel consisting of SAA, SS-TTR, and known MI biomarker myoglobin.
The collaboration aims to turn IBI's mass-spec immunoassay technology from a tool it has offered exclusively on a contract-research basis into a turnkey product available to clinical research laboratories around the world.
